Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Abzena in talks to monetise royalty-bearing Inside products

The life sciences group said earlier this month it will need to raise money in order to support its plans, and it is looking at selling off a chunk of the future royalties from some of its Abzena Inside products
dna double helix
Abzena Inside products are used in other drugs to improve their safety and efficacy

Life sciences group Abzena plc (LON:ABZA) is in talks to monetise its royalty-bearing Abzena Inside products as it looks to secure its financial future.

The AIM-quoted firm reported earlier this month that additional working capital would be required over the coming year to support it.

READ: Period of transition for Abzena

It has signed a non-binding agreement with an unnamed and unconnected third party which, if the deal is confirmed, will pay Abzena an upfront fee in return for a chunk of the future royalties generated by certain Abzena Inside products.

The two parties have now entered into a limited period of exclusivity for the completion of due diligence and negotiation of a definitive agreement.

Following talks with several institutional investors and shareholders, the company decided this was the best way of raising funds.

“The board believes that, if completed, the funds received will be sufficient for the group's short term working capital needs,” read the statement.

Abzena added that it will continue to explore near-term funding options, including equity and/ or debt financing.

Inside products

Abzena specialises in developing technologies that can be added to a drug to improve its delivery, safety profile and effectiveness.

There are currently 12 therapeutic antibodies produced using Abzena’s antibody humanisation technology being progressed through clinical development by its partners.

Each one has the potential to generate license fees, milestone payments and/or royalties for Abzena.

View full ABZA profile View Profile

Abzena plc Timeline

Related Articles

Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"
3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use